Pfizer has a VEGF bispecific strategy. And it’s very different than Summit’s

As Wall Street continues to digest this week’s disappointing results for Summit Therapeutics’ PD-1xVEGF bispecific cancer drug, one competitor is primed to take advantage. Summit’s stock {$SMMT} closed 20% lower on Monday ...